US Patent Issued to Phio Pharmaceuticals on Oct. 6 for "Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy" (Swedish, American Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,407, issued on Oct. 6, was assigned to Phio Pharmaceuticals Corp. (King of Prussia, Pa.).

"Chemically modified oligonucleotides targeting bromodomain containing protein 4 (BRD4) for immunotherapy" was invented by James Cardia (Franklin, Mass.), Rolf Kiessling (Stockholm) and Jeroen Melief (Sollentuna, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates, in some aspects, to methods and compositions for production of immunomodulatory compositions. In some embodiments, the disclosure provides host cells which have been treated ex vivo with one or more oligonucleotide agents capable of controlling and/or reducing the differentiat...